Excellent diagnostic performance: 91% sensitivity, 94% specificity, and 93% diagnostic accuracy
This lesion-level pooled data analysis of 588 patients and 700 lesions represents the “largest and most diverse cohort of any single angiogram-based FFR technology reported.” Results indicate FFRangio has excellent diagnostic performance, strong correlation, and that results were robust across a wide spectrum of patients and lesion characteristics.
Excellent diagnostic performance, with sensitivity, specificity and accuracy all above 92%; FFRangio was 40% faster that wire-based FFR
This prospective clinical study conducted at Gifu Heart Centre, Japan—evaluated the diagnostic performance of FFRangio in 50 patients with dual or triple vessel CAD compared to wire-based FFR. Continue reading “FFRangio in Dual/Triple Vessel Disease”
92% Diagnostic Accuracy, 94% Sensitivity, and 91% Specificity
The FAST-FFR pivotal trial was a prospective multicenter, international trial designed to determine the accuracy of FFRangio in clinical practice compared to traditional wire-based FFR. The trial included 301 patients and 319 vessels at 10 clinical sites. The results demonstrated excellent diagnostic performance, including in the grey zone between FFR values of 0.75 and 0.85. Continue reading “FAST-FFR Pivotal Trial”
High concordance with invasive FFR wires, 93% diagnostic accuracy
The FFRangio Validation study evaluated 203 lesions in 184 patients and showed that there is high concordance between FFRangio and invasive FFR, including a diagnostic accuracy of 93%. Continue reading “FFRangio Validation Study”